A Study of Glycemic Control in Left Ventricular Assist
(GLYCEM1C-LVAD Trial)
Trial Summary
What is the purpose of this trial?
The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.
Research Team
Andrew Rosenbaum, MD
Principal Investigator
Mayo Clinic
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants use the Freestyle Libre 3 CGM to monitor blood sugar levels continuously and compare with hemoglobin A1c over a 3-month period
Follow-up
Participants are monitored for safety and effectiveness after treatment, including adjustments to antihyperglycemic agents
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor